NeuroPace delivered a strong fourth quarter with 24% revenue growth and significant gross margin expansion, reaching $26.6 million in total revenue. The company achieved its second consecutive quarter of positive Adjusted EBITDA and made strategic progress with FDA submissions for IGE indication and AI-driven tools.

NeuroPace achieved its highest-ever quarterly revenue in Q2 2025, reaching $23.5M. Gross profit improved significantly with margin expanding to 77.1%. Despite higher operating expenses, net loss narrowed slightly. The company also increased full-year guidance for revenue and gross margin.

NeuroPace delivered record Q1 2025 revenue of $22.5 million, supported by growth in its core RNS System line and strong gross margins. Net loss narrowed compared to the prior year, and the company ended the quarter with a robust cash position.

NeuroPace achieved record Q4 2024 revenue of $21.5 million, reflecting a 19% year-over-year increase, primarily driven by strong sales of the RNS System. The company reported a net loss of $5.3 million, an improvement from the $6.2 million loss in Q4 2023. Operating expenses increased slightly due to higher investments in R&D and sales efforts. Gross margin reached 75.4%, exceeding guidance. The company completed a $74.8 million public offering in February 2025 to strengthen its balance sheet and fund future growth initiatives.

NeuroPace reported a 28% year-over-year increase in revenue to $21.1 million in Q3 2024. The company also demonstrated operating discipline by decreasing cash burn. Increased full-year 2024 revenue guidance to $78 million to $80 million.

NeuroPace reported a 17% increase in revenue to $19.3 million for Q2 2024, driven by increased sales of the RNS System. The gross margin expanded to 73.4%. The company decreased cash burn to $4.0 million, demonstrating operating discipline and increased full-year 2024 revenue guidance to $76 million to $78 million.

NeuroPace reported a 25% increase in revenue to $18.1 million for Q1 2024 compared to Q1 2023. The company's gross margin was 73.6%, and it extended the maturity date of its term loan by one year to September 30, 2026. The company maintained full-year 2024 revenue guidance of $73 to $77 million.

NeuroPace announced record full year 2023 revenue of $65.4 million. Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022. The company provides full-year 2024 revenue guidance of between $73-$77 million.

NeuroPace reported a 47% year-over-year increase in revenue for Q3 2023, reaching $16.4 million. The company reduced cash burn to $2.2 million and increased full-year revenue guidance to $62.5-$63.5 million.

NeuroPace reported a strong second quarter with a 62% increase in revenue year-over-year, driven by increased utilization of the RNS System and meaningful revenue from DIXI Medical products. The company also reduced its cash burn and increased its full-year revenue guidance.

NeuroPace reported a 27% year-over-year increase in revenue for Q1 2023, reaching $14.5 million. The growth was attributed to increased utilization of the RNS System and contributions from DIXI Medical products. The company increased its full-year revenue guidance to $52-$54 million.

NeuroPace reported a 16% increase in total revenue for Q4 2022, reaching $12.8 million. This growth was driven by a 15% increase in initial implant revenue and contributions from the distribution of DIXI Medical products. The company's net loss for the quarter was $11.1 million.

NeuroPace reported an $11.2 million total revenue for Q3 2022, which represents an 8% growth compared to Q3 2021. The company also initiated distribution of DIXI Medical's stereo EEG product portfolio and implanted the first patient in the NAUTILUS pivotal study.

NeuroPace reported a decrease in total revenue to $10.2 million, compared to $12.6 million in the prior year period. The company's net loss increased to $12.7 million, compared to a net loss of $8.5 million in the prior year period. Despite these challenges, the operating environment improved throughout the second quarter, with a positive trend continuing into the third quarter.

NeuroPace reported total revenue of $11.4 million for Q1 2022, a slight increase from $11.2 million in the prior year period. Initial implant revenue was $8.8 million, while replacement implant revenue was $2.6 million. The company's net loss for the quarter was $11.5 million.

NeuroPace reported a 2% increase in total revenue for Q4 2021, reaching $11.0 million, with initial implant revenue increasing by 10% to $8.5 million, while replacement implant revenue decreased by 19% to $2.5 million. The company's net loss for the quarter was $10.7 million, compared to a net loss of $4.6 million in the prior year period.

NeuroPace reported a total revenue of $10.3 million for Q3 2021, a 19% decrease compared to the prior year period. The decrease was attributed to COVID-19 related headwinds. The company continues to make progress toward increasing the market opportunity. Management provided updated full-year 2021 guidance.

NeuroPace reported a strong second quarter with a 65% increase in total revenue, driven by a 100% increase in initial implant revenue. The company is progressing with its plans to expand the indication of its RNS System and is on track to begin enrolling patients before the end of the year.

NeuroPace reported a 12% increase in total revenue, reaching $11.2 million, and a 23% increase in initial implant revenue, totaling $8.1 million for the first quarter of 2021. The company completed an initial public offering, raising approximately $105 million in net proceeds and issued 2021 total revenue guidance of approximately $47 million, representing 14% growth compared to 2020.